(Q33874502)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10735935%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

review article

1 reference

title

Chemotherapy and management of bladder tumours (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10735935%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10735935%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

author name string

C N Sternberg

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10735935%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

publication date

1 March 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10735935%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10735935%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

volume

85

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10735935%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

page(s)

599-610

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10735935%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10735935%20AND%20SRC:MED&resulttype=core&format=json

Staging invasive bladder tumors

5 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2000.00566.X

The role of pelvic lymphadenectomy and radical cystectomy for lymph node positive bladder cancer. The Memorial Sloan-Kettering Cancer Center experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2000.00566.X

The treatment of advanced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2000.00566.X

Neoadjuvant and adjuvant chemotherapy in advanced disease--what are the effects on survival and prognosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2000.00566.X

Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2000.00566.X

Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2000.00566.X

The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2000.00566.X

Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2000.00566.X

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2000.00566.X

Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2000.00566.X

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2000.00566.X

Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2000.00566.X

Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2000.00566.X

Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2000.00566.X

Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2000.00566.X

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2000.00566.X

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2000.00566.X

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2000.00566.X

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2000.00566.X

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2000.00566.X

Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2000.00566.X

Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2000.00566.X

p53 nuclear immunoreactivity as a predictor of response and outcome following chemotherapy for metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2000.00566.X

Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2000.00566.X

Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2000.00566.X

p53 and treatment of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2000.00566.X

10.1046/J.1464-410X.2000.00566.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10735935%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference